Skip Navigation LinksHome > December 2013 - Volume 56 - Issue 4 > Controversies in Osteoporosis Management: Concerns About Bis...
Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e3182a98295
Controversies in Osteoporosis Management

Controversies in Osteoporosis Management: Concerns About Bisphosphonates and When Are “Drug Holidays” Required?

MCCLUNG, MICHAEL MD

Collapse Box

Abstract

Bisphosphonates are effective treatments for osteoporosis. The pharmacology and observance of atypical femoral fractures in patients on long-term therapy raise questions about the need for intermittent discontinuation of treatment, a “drug holiday.” Fracture protection benefits of bisphosphonate therapy far outweigh the risk of atypical fractures for the first 10 years of therapy. However, because the fracture probability of therapy abates slowly after stopping the treatment while the risk of atypical fracture appears to decrease quickly, a “drug holiday” of 1 to 2 years should be considered after 3 to 5 years of bisphosphonate therapy except in those patients who remain at very high fracture risk.

© 2013, Lippincott Williams & Wilkins

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.